Comment: Why are females with Fabry disease affected?

[1]  T. Cox,et al.  Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and management. , 2017, Molecular genetics and metabolism.

[2]  A. Hagège,et al.  X‐chromosome inactivation in female patients with Fabry disease , 2016, Clinical genetics.

[3]  P. Meikle,et al.  Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts. , 2015, Molecular genetics and metabolism.

[4]  R. Giugliani,et al.  Are MPS II heterozygotes actually asymptomatic? A study based on clinical and biochemical data, X‐inactivation analysis and imaging evaluations , 2011, American journal of medical genetics. Part A.

[5]  C. Eng,et al.  Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome) , 2008, Pediatrics.

[6]  M. Elleder,et al.  Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the α-galactosidase A gene in the Czech and Slovak population , 2005, Journal of Molecular Medicine.

[7]  O. Bodamer,et al.  Mucopolysaccharidosis type II in females: case report and review of literature. , 2005, Pediatric neurology.

[8]  William B Dobyns,et al.  Inheritance of most X‐linked traits is not dominant or recessive, just X‐linked , 2004, American journal of medical genetics. Part A.

[9]  J. Kriegsmann,et al.  Anderson–Fabry disease: Clinical manifestations of disease in female heterozygotes , 2001, Journal of Inherited Metabolic Disease.

[10]  B. Migeon.  Non-random X chromosome inactivation in mammalian cells , 1998, Cytogenetic and Genome Research.